Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate.

Abstract:

:Vaccination is considered the most cost-effective approach to preventing infectious diseases, yet better formulations and delivery methods for efficient distribution and administration of vaccines are needed, especially for low-resource settings. A fast-dissolving tablet (FDT) that could be packaged in a compact stackable blister sheet is a potentially attractive option for formulating oral vaccines, since it would minimally impact the cold chain and could potentially be administered directly to patients without reconstitution. This study focused on using one component of a live attenuated trivalent vaccine under development to produce a FDT for the prevention of diarrhea induced by enterotoxigenic Escherichia coli (ETEC). Ten formulations were prepared and freeze dried to produce FDTs. Three freezing conditions were explored, along with different drying and package sealing methods. Physical properties examined included structural integrity, dissolution time, moisture content, and glass transition temperature. Bacterial viability was tested by assaying for colony-forming units. The formulation compositions and freeze-drying parameters were adjusted in an iterative process to arrive at a promising formulation for the ETEC vaccine tablet. This formulation included sucrose and trehalose as cryoprotectants; phosphate and glutamate salts as buffers and stabilizers; and Natrosol(®), polyvinylpyrrolidone, and mannitol as binders. The process loss in viability during freeze drying was less than 0.3 log 10 (50% recovery) for the optimized vaccine tablet formulation. The final tablets were robust, disintegrated in less than 10s, and preserved the bacteria at 2-8°C for at least 12 months with less than 0.4 log 10 loss (40% recovery) in viability during storage. This study indicates that the FDT produced by freeze drying directly in a blister sheet could be a practical option for formulating ETEC vaccines for oral immunization and help to facilitate delivery of lifesaving vaccines, particularly in low-resource settings.

journal_name

Vaccine

journal_title

Vaccine

authors

Lal M,Priddy S,Bourgeois L,Walker R,Pebley W,Brown J,Desai J,Darsley MJ,Kristensen D,Chen D

doi

10.1016/j.vaccine.2013.08.010

subject

Has Abstract

pub_date

2013-10-01 00:00:00

pages

4759-64

issue

42

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(13)01094-3

journal_volume

31

pub_type

杂志文章

相关文献

VACCINE文献大全
  • The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?

    abstract::HPV vaccines are highly immunogenic. A two-dose schedule for 9-14 year-old is recommended. However, no data exist regarding the impact of age, menarche status and body mass index (BMI) on the immune response to a two-dose schedule. In this post-hoc analysis, we present antibody titers to HPV6/11/16/18 in 9-13 year-old...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2019.09.089

    authors: Sauvageau C,Gilca V,Donken R,Fan SY,Ogilvie G,Dobson S

    更新日期:2019-11-20 00:00:00

  • Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

    abstract::Antibodies specific for Vibrio cholerae lipopolysaccaride (LPS) are common in humans recovering from cholera, and constitute a primary component of the vibriocidal response, a serum complement-mediated bacteriocidal response correlated with protection against cholera. In order to determine whether transcutaneous immun...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.040

    authors: Rollenhagen JE,Kalsy A,Saksena R,Sheikh A,Alam MM,Qadri F,Calderwood SB,Kovác P,Ryan ET

    更新日期:2009-08-06 00:00:00

  • Is freezing in the vaccine cold chain an ongoing issue? A literature review.

    abstract::Vaccine exposure to temperatures below recommended ranges in the cold chain may decrease vaccine potency of freeze-sensitive vaccines leading to a loss of vaccine investments and potentially places children at risk of contracting vaccine preventable illnesses. This literature review is an update to one previously publ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2016.09.070

    authors: Hanson CM,George AM,Sawadogo A,Schreiber B

    更新日期:2017-04-19 00:00:00

  • Impact of measles national vaccination coverage on burden of measles across 29 Member States of the European Union and European Economic Area, 2006-2011.

    abstract:BACKGROUND:Challenges in reaching good vaccination coverage against measles emerged in several European Union/European Economic Area Member States (EU/EEA MS) leading to progressive accumulation of susceptible individuals and outbreaks. The Burden of Communicable Diseases in Europe (BCoDE) project developed a methodolo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.01.094

    authors: Colzani E,McDonald SA,Carrillo-Santisteve P,Busana MC,Lopalco P,Cassini A

    更新日期:2014-04-01 00:00:00

  • Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults.

    abstract::T-lymphocyte responses to influenza vaccination were measured in healthy young and older adult volunteers. All participants were vaccinated with the 1995-96 trivalent influenza vaccine. Cytokine and granzyme B levels were measured in peripheral blood mononuclear cells (PBMC) cultures after virus stimulation, prior to ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00133-9

    authors: McElhaney JE,Upshaw CM,Hooton JW,Lechelt KE,Meneilly GS

    更新日期:1998-11-01 00:00:00

  • Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain.

    abstract::Two rotavirus vaccines have been available since 2006. This study evaluates the effectiveness of these vaccines using a test-negative case-control design in Navarre, Spain. We included children 3-59 months of age who sought medical care for gastroenteritis and for whom stool samples were taken between January 2008 and...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.071

    authors: Castilla J,Beristain X,Martínez-Artola V,Navascués A,García Cenoz M,Alvarez N,Polo I,Mazón A,Gil-Setas A,Barricarte A

    更新日期:2012-01-11 00:00:00

  • Risk factors for measles in children aged 8 months-14 years in China after nationwide measles campaign: A multi-site case-control study, 2012-2013.

    abstract:INTRODUCTION:Endemic measles persists in China, despite >95% reported coverage of two measles-containing vaccine doses and nationwide campaign that vaccinated more than 100 million children in 2010. In 2011, almost half of the 9943 measles cases in China occurred in children eligible for measles vaccination. We conduct...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2016.02.005

    authors: Hao L,Ma C,Wannemuehler KA,Su Q,An Z,Cairns L,Quick L,Rodewald L,Liu Y,He H,Xu Q,Ma Y,Yu W,Zhang N,Li L,Wang N,Luo H,Wang H,Gregory CJ

    更新日期:2016-12-12 00:00:00

  • Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.

    abstract::The prevalence of seropositive individuals that makes costs of vaccinating all individuals equal to that for screening and vaccination of susceptible individuals is defined as the critical prevalence of antibodies (p*). Screening and vaccination is more efficient when the prevalence of seropositive individuals (p) in ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.03.048

    authors: Plans-Rubió P

    更新日期:2004-09-28 00:00:00

  • Capacity for a global vaccine safety system: the perspective of national regulatory authorities.

    abstract::Confidence in vaccine safety is critical to national immunization strategies and to global public health. To meet the Millenium Development Goals, and buoyed by the success of new vaccines produced in developing countries, the World Health Organization has been developing a strategy to establish a global system for ef...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.045

    authors: Graham JE,Borda-Rodriguez A,Huzair F,Zinck E

    更新日期:2012-07-13 00:00:00

  • Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.

    abstract:BACKGROUND:Two MenB vaccines with different dosing schedules are approved in the US: MenB-4C (2 doses) and MenB-FHbp (2-3 doses). Both vaccines were licensed on the basis of immunogenicity demonstrated after vaccine series completion. We evaluated vaccination completion and adherence to dosing schedules. METHODS:This ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.06.065

    authors: Packnett E,Irwin DE,Novy P,Watson PS,Whelan J,Moore-Schiltz L,Lucci M,Hogea C

    更新日期:2019-09-16 00:00:00

  • Purification of O-specific polysaccharide from lipopolysaccharide produced by Salmonella enterica serovar Paratyphi A.

    abstract::The O specific polysaccharide (OSP) of the lipopolysaccharide (LPS) of Salmonella enterica serovar Paratyphi A is a protective antigen and the target for vaccine development. LPS is the major constituent of the outer membrane of S. Paratyphi A with the OSP exposed on the surface, in addition to the cell associated LPS...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.090

    authors: Kothari S,Kim JA,Kothari N,Jones C,Choe WS,Carbis R

    更新日期:2014-05-01 00:00:00

  • Vaccination with whole-cell vaccine and bacterial protein extract protects tilapia against Streptococcus difficile meningoencephalitis.

    abstract::Formalin-killed Streptococcus difficile strains used as vaccines delivered intraperitoneally were able to protect tilapia against a challenge of 100 LD50. The protection obtained was not strain specific. A vaccine based on an S. difficile extract containing 50% protein conjugated to alum also protected tilapia challen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)00067-w

    authors: Eldar A,Shapiro O,Bejerano Y,Bercovier H

    更新日期:1995-06-01 00:00:00

  • A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.

    abstract:BACKGROUND:The severe acute respiratory syndrome (SARS) virus is a member of the Coronaviridae (CoV) family that first appeared in the Guangdong Province of China in 2002 and was recognized as an emerging infectious disease in March 2003. Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.09.026

    authors: Martin JE,Louder MK,Holman LA,Gordon IJ,Enama ME,Larkin BD,Andrews CA,Vogel L,Koup RA,Roederer M,Bailer RT,Gomez PL,Nason M,Mascola JR,Nabel GJ,Graham BS,VRC 301 Study Team.

    更新日期:2008-11-25 00:00:00

  • Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.

    abstract:OBJECTIVE:This study sought to evaluate the acceptability of inactivated influenza vaccine delivered by microneedle patch (MNP) in comparison to inactivated influenza vaccine (IIV) delivered by hypodermic needle. DESIGN, SETTING, AND PARTICIPANTS:From the general population of Atlanta, Georgia, we screened 112 and enr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.07.064

    authors: Frew PM,Paine MB,Rouphael N,Schamel J,Chung Y,Mulligan MJ,Prausnitz MR

    更新日期:2020-10-21 00:00:00

  • A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.

    abstract::West Nile virus (WNV) has caused multiple global outbreaks with increased frequency of neuroinvasive disease in recent years. Despite many years of research, there are no licensed therapeutics or vaccines available for human use. One of the major impediments of vaccine development against WNV is the potential enhancem...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.02.073

    authors: Lai H,Paul AM,Sun H,He J,Yang M,Bai F,Chen Q

    更新日期:2018-03-27 00:00:00

  • Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules.

    abstract::Human papillomavirus type 16 (HPV16)-transformed mouse TC-1 cells are extensively used in the evaluation of efficacy of experimental vaccines against tumours induced by HPVs. As these cells strongly express MHC class I molecules and downregulation of MHC class I surface expression is one of the important mechanisms th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00519-4

    authors: Smahel M,Síma P,Ludvíková V,Marinov I,Pokorná D,Vonka V

    更新日期:2003-03-07 00:00:00

  • Methods for systematic reviews of administrative database studies capturing health outcomes of interest.

    abstract::This report provides an overview of methods used to conduct systematic reviews for the US Food and Drug Administration (FDA) Mini-Sentinel project, which is designed to inform the development of safety monitoring tools for FDA-regulated products including vaccines. The objective of these reviews was to summarize the l...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2013.06.048

    authors: McPheeters ML,Sathe NA,Jerome RN,Carnahan RM

    更新日期:2013-12-30 00:00:00

  • Immunotherapy with combined DNA vaccines is an effective treatment for M. bovis infection in cattle.

    abstract::Mycobacterium bovis causes tuberculosis in cattle. Because current therapies inadequately prevent disease spread, new therapies for M. bovis infections are urgently needed. We treated M. bovis-infected cattle with combinations of DNA vaccines, resulting in significantly reduced pulmonary bacterial loads compared with ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.12.055

    authors: Hu XD,Chen ST,Yu DH,Li SX,Cai H

    更新日期:2009-02-25 00:00:00

  • Influenza vaccination of future healthcare workers: a cross-sectional study of uptake, knowledge and attitudes.

    abstract::Promotional campaigns recommend immunisation against influenza in healthcare workers (HCWs) but the uptake in this group remains low. We conducted a survey study during the 2008-2009 influenza vaccination period amongst future HCWs to quantify uptake and identify barriers to immunisation. Overall uptake was 8.0% (95% ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.04.066

    authors: Blank DL,Bodansky DM,Forbes A,Garde E,Story F,Roalfe AK,Tait L

    更新日期:2010-06-23 00:00:00

  • Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.

    abstract::The development of potent adjuvants, conditioning innate and adaptative immunity, particularly CTL responses, has become currently a hot point in the rational design of vaccines for cancer immunotherapy. We have described a new approach, in which gangliosides are incorporated into vesicles from Neisseria meningitidis ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.111

    authors: Mesa C,de León J,Fernández LE

    更新日期:2006-03-24 00:00:00

  • Development pathway for biodefense vaccines.

    abstract::At the present time it is estimated that the process of development of a vaccine from discovery to licensure takes approximately 18-20 years and costs in excess of US$500 million. For "routine" vaccines, the case for developing a vaccine is straightforward in terms of economics and large scale public health utilizatio...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2009.07.094

    authors: Barrett AD,Beasley DW

    更新日期:2009-11-05 00:00:00

  • Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate.

    abstract::Tuberculosis (TB) is the second leading cause of death by infectious disease worldwide. The only available TB vaccine is the Bacille Calmette-Guerin (BCG). However, parenterally administered Mycobacterium bovis BCG vaccine confers only limited immune protection from pulmonary tuberculosis in humans. There is a need fo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.04.090

    authors: Shen CF,Jacob D,Zhu T,Bernier A,Shao Z,Yu X,Patel M,Lanthier S,Kamen A

    更新日期:2016-06-17 00:00:00

  • Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

    abstract::Previous studies with the malaria vaccine RTS,S/AS02(A) in young children in a malaria endemic area of Mozambique have shown it to have a promising safety profile and to reduce the risk of Plasmodium falciparum infection and disease. In this study, we assessed the antibody responses to the P. falciparum and hepatitis ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2011.03.041

    authors: Aide P,Dobaño C,Sacarlal J,Aponte JJ,Mandomando I,Guinovart C,Bassat Q,Renom M,Puyol L,Macete E,Herreros E,Leach A,Dubois MC,Demoitie MA,Lievens M,Vekemans J,Loucq C,Ballou WR,Cohen J,Alonso PL

    更新日期:2011-08-11 00:00:00

  • Tetanus, diphtheria and acellular pertussis (Tdap) vaccination among healthcare personnel-United States, 2011.

    abstract:BACKGROUND:Health-care personnel (HCP) are at risk for exposure to and possible transmission of vaccine-preventable diseases. Receiving recommended vaccines is an essential prevention practice for HCP to protect themselves and their patients. The tetanus, diphtheria and acellular pertussis vaccine (Tdap) was recommende...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.11.077

    authors: Lu PJ,Graitcer SB,O'Halloran A,Liang JL

    更新日期:2014-01-23 00:00:00

  • Considerations for controlling invasive meningococcal disease in high income countries.

    abstract::The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income c...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2011.12.093

    authors: Holst J,Nøkleby H,Bettinger JA

    更新日期:2012-05-30 00:00:00

  • Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert.

    abstract::A recombinant fowlpox vaccine with an H5 hemagglutinin gene insert protected chickens against clinical signs and death following challenge by nine different highly pathogenic H5 avian influenza viruses. The challenge viruses had 87.3 to 100% deduced hemagglutinin amino acid sequence similarity with the recombinant vac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00369-2

    authors: Swayne DE,Garcia M,Beck JR,Kinney N,Suarez DL

    更新日期:2000-01-06 00:00:00

  • A comparison of different vaccination schemes used in sheep combining inactivated bluetongue vaccines against serotypes 4 and 8.

    abstract::Eight different vaccination schemes using four commercially available inactivated Bluetongue vaccines against serotypes 4 and 8 in three different combinations (setting 1-3) were tested under field conditions for their ability to generate a measurable immune response in sheep. Animals of setting 1 (groups A-D) were si...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.08.011

    authors: Hilke J,Strobel H,Woelke S,Stoeter M,Voigt K,Grimm L,Meilwes J,Punsmann T,Blaha I,Salditt A,Rohn K,Bastian M,Ganter M

    更新日期:2019-09-16 00:00:00

  • The role of IL-10 and IgG1 in the protection and granulomatous response in Schistosoma mansoni P24-immunized mice.

    abstract::Previous work by our laboratory identified a fraction of Schistosoma mansoni soluble adult worm antigenic preparation, designated PIII, able to elicit significant in vitro cell proliferation, and lower in vitro and in vivo granuloma formation. In the present work, we investigated some biological activities of P24, an ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00265-6

    authors: Zouain CS,Gustavson S,Oliveira SC,Azevedo V,Alves JB,Goes AM

    更新日期:2000-12-08 00:00:00

  • Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71.

    abstract::Enterovirus 71 (EV71) causes seasonal epidemics of hand-foot-and-mouth disease associated with fatal neurological complications in young children, and several major outbreaks have occurred recently. This study developed an effective antiviral agent by transforming the gene for VP1 protein, a previously defined epitope...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.12.047

    authors: Chen HF,Chang MH,Chiang BL,Jeng ST

    更新日期:2006-04-05 00:00:00

  • Cost-effectiveness of mass dog rabies vaccination strategies to reduce human health burden in Flores Island, Indonesia.

    abstract::The cost-effectiveness of different mass dog rabies vaccination strategies, defined as the costs per year of life lost (YLL) averted was evaluated for a period of 10 years by means of a dynamic simulation study for a typical village on Flores Island. In the base strategy (no dog vaccination and no post-exposure treatm...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.10.009

    authors: Wera E,Mourits MCM,Hogeveen H

    更新日期:2017-12-04 00:00:00